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ABSTRACT
Objective: To determine whether low vitamin D concentrations are associated with an increased
risk of incident all-cause dementia and Alzheimer disease.
Methods: One thousand six hundred fifty-eight elderly ambulatory adults free from dementia,
cardiovascular disease, and stroke who participated in the US population–based Cardiovascular
Health Study between 1992–1993 and 1999 were included. Serum 25-hydroxyvitamin D (25
(OH)D) concentrations were determined by liquid chromatography-tandem mass spectrometry
from blood samples collected in 1992–1993. Incident all-cause dementia and Alzheimer disease
status were assessed during follow-up using National Institute of Neurological and Communica-
tive Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association criteria.
Results: During a mean follow-up of 5.6 years, 171 participants developed all-cause dementia,
including 102 cases of Alzheimer disease. Using Cox proportional hazards models, the multivar-
iate adjusted hazard ratios (95% confidence interval [CI]) for incident all-cause dementia in par-
ticipants who were severely 25(OH)D deficient (,25 nmol/L) and deficient ($25 to ,50 nmol/L)
were 2.25 (95% CI: 1.23–4.13) and 1.53 (95% CI: 1.06–2.21) compared to participants with
sufficient concentrations ($50 nmol/L). The multivariate adjusted hazard ratios for incident
Alzheimer disease in participants who were severely 25(OH)D deficient and deficient compared
to participants with sufficient concentrations were 2.22 (95%CI: 1.02–4.83) and 1.69 (95%CI:
1.06–2.69). In multivariate adjusted penalized smoothing spline plots, the risk of all-cause
dementia and Alzheimer disease markedly increased below a threshold of 50 nmol/L.
Conclusion: Our results confirm that vitamin D deficiency is associated with a substantially
increased risk of all-cause dementia and Alzheimer disease. This adds to the ongoing debate
about the role of vitamin D in nonskeletal conditions. Neurology® 2014;83:920–928
GLOSSARY
25(OH)D 5 25-hydroxyvitamin D; AD 5 Alzheimer disease; BMI 5 body mass index; CHS 5 Cardiovascular Health Study;
CI 5 confidence interval; HR 5 hazard ratio; LC-MS 5 liquid chromatography-tandem mass spectrometry; NINCDS-
ADRDA 5 National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and Related
Disorders Association.
Recent meta-analyses confirm that low serum vitamin D concentrations are associated with
prevalent Alzheimer disease (AD) dementia and cognitive impairment.1–3 This is cause for
concern given the high rates of vitamin D deficiency in older adults4 and continued uncertainty
about the causes of AD and other forms of dementia.5 Both the 1,25-dihydroxyvitamin D3
receptor and 1a-hydroxylase, the enzyme responsible for synthesizing the bioactive form of
vitamin D, are found throughout the human brain.6 In vitro, vitamin D increases the phagocytic
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clearance of amyloid plaques by stimulating
macrophages7,8 and reduces amyloid-induced
cytotoxicity and apoptosis in primary cortical
neurons.9 Vitamin D deficiency has also been
linked to vascular dysfunction and ischemic
stroke risk10 as well as brain atrophy.11 How-
ever, reverse causation is also possible, as the
onset of dementia may lead to dietary changes
and reduced outdoor activity, which in turn
result in lower vitamin D concentrations.12
Previous prospective studies have established
that low vitamin D concentrations in elderly
adults are associated with an increased risk of
cognitive decline.3,13–15 Furthermore, it has been
hypothesized that the risk of cognitive decline
markedly increases below a threshold between
25 and 50 nmol/L.12 However, preliminary
prospective studies of vitamin D and dementia
risk have been discordant. In a small study of 40
high-functioning elderly women, severe vitamin
D deficiency (,25 nmol/L) was associated with
a higher risk of non-AD dementias but not AD
over 7 years.16 In contrast, in 10,186 individu-
als, severe vitamin D deficiency was associated
with medical records indicating AD but not vas-
cular dementia over 30 years of follow-up.17 The
discrepancy in these findings may be due to a
lack of statistical power16 or use of unstandard-
ized dementia diagnoses from medical records,
which may result in considerable misclassifi-
cation.17 We therefore conducted what is to
our knowledge the first large, prospective,
population-based study incorporating a com-
prehensive adjudicated assessment of demen-
tia and AD to examine their relationship with
vitamin D concentrations.
METHODS Participants. Participants were selected from the
Cardiovascular Health Study (CHS), a large, prospective,
population-based study in the United States designed to
investigate the underlying causes of cardiovascular disease in older
men and women.18 The CHS recruited participants from 4
communities: Forsyth county, NC (36.1° north, 80.3° west);
Sacramento county, CA (38.5° north, 121.4° west); Washington
county, MD (39.6° north, 77.8° west); and Pittsburgh, PA (40.4°
north, 80.0° west). The cohort consisted of 5,201 adults recruited
in 1989–1990 and an additional 687 African-American participants
recruited in 1992–1993. Of these 5,888 participants, 4,692
ambulatory participants had complete exam data in 1992–1993 (the
baseline assessment for the current study). Serum 25-hydroxyvitamin
D (25(OH)D) concentrations were not measured in 1,424
participants who had prevalent cardiovascular disease or
stroke (one or more of the following: coronary heart disease,
congestive heart failure, claudication, atrial fibrillation,
pacemaker, implantable cardioverter defibrillator, stroke, or
TIA), determined by medical records, ECG findings, and self-
report.19 Further exclusions were insufficient serum volumes for
vitamin D assay to be performed (,500 mL; n 5 945) and
missing adjudicated dementia status (n 5 596).20 Participants
with prevalent dementia at the time of the vitamin D collection
(n 5 69) were excluded from the main analyses but included in
secondary analyses of prevalent dementia. This resulted in a final
sample of 1,658 participants for the main prospective analyses and
1,727 participants for the secondary baseline analyses. Those lost to
follow-up (defined as participants with serum 25(OH)D measured
but no diagnostic assessment of incident dementia) were older
(mean [SD], 74.3 [5.4] years vs 73.8 [4.6] years, p 5 0.03), were
more likely to be nonwhite (20.0% vs 13.1%, p, 0.001), and had
lower serum 25(OH)D concentrations (mean [SD], 61.2 [39.4]
nmol/L vs 64.4 [26.5] nmol/L, p 5 0.03), but they were no
more likely to be female (71.4% vs 69.2%, p 5 0.31) or less
educated (27.4% vs 23.4% did not finish high school, 53% vs
54% finished high school/some college/vocational qualifications,
and 19.6% vs 22.6% completed college or professional
qualifications, p 5 0.10).
Standard protocol approvals, registrations, and patient
consents. The institutional review boards at each participating
institution approved the research protocols, and all participants
provided written informed consent.
Serum 25(OH)D measurement. Serum samples collected in
1992–1993 were stored at270 °C at the Laboratory for Clinical
Biochemistry Research at the University of Vermont, and measure-
ments were performed by the University of Washington Clinical
Nutrition Research Unit in 2008.21 Total 25(OH)D (the sum
of 25(OH)D2 and 25(OH)D3) was measured using liquid
chromatography-tandem mass spectrometry (LC-MS) on a
Waters Quattro micro mass spectrometer (Waters, Milford, MA);
the interassay coefficient of variation was ,3.4%.19 Calibration of
serum 25(OH)D concentrations was verified using SRM 972 from
the National Institute of Standards and Technology.22
Diagnosis of all-cause dementia and AD. Dementia and AD
status was assessed in 1998–1999 by a committee of neurologists
and psychiatrists on the basis of annual cognitive assessments,
repeat MRI scans, medical records, questionnaires, and proxy
interviews. Diagnosis of dementia was based on a progressive or
static cognitive deficit with impairment in at least 2 cognitive
domains and a history of normal cognitive function before the
onset of abnormalities. Incident all-cause dementia and AD were
diagnosed according to the National Institute of Neurological and
Communicative Diseases and Stroke/Alzheimer’s Disease and
Related Disorders Association (NINCDS-ADRDA) criteria.
Further details can be found elsewhere.23
Covariates. We adjusted for covariates identified as potential
confounders1–3,12: age in years, season of blood collection
(December–February, March–May, June–August, September–
November), education status (did not finish high school, finished
high school/some college/vocational qualifications, completed
college/professional qualifications), sex, body mass index (BMI
in kg/m2), smoking (nonsmoker, current smoker), alcohol con-
sumption (National Institute on Alcohol Abuse and Alcoholism
definitions: nondrinkers, moderate drinkers [women #7 drinks/
week; men #14 drinks/week], heavy drinkers [women .7
drinks/week; men .14 drinks/week]), and significant depressive
symptoms (score $8 on the revised 10-item Center for
Epidemiologic Studies Depression Scale24).
Statistical analysis. Cox proportional hazards models were used
to assess the associations between baseline serum 25(OH)D and
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the risk of incident all-cause dementia and AD. Participants were
considered at risk for dementia from baseline (1992–1993) and
were censored at death or the end of follow-up in June 1999. All-
cause dementia included AD cases, and analyses for AD were
censored for non-AD dementia. The proportionality of hazards
assumption was assessed using the Schoenfeld residuals
Table 1 Baseline characteristics of 1,658 CHS participants by serum 25(OH)D concentration
Characteristic
Serum 25(OH)D, nmol/L
All (n 5 1,658) ‡50 (n 5 1,169)
‡25 to <50
(n 5 419) <25 (n 5 70)
Age, y, mean (SD) 73.6 (4.5) 73.6 (4.4) 73.7 (4.6) 74.1 (5.1)
Season tested, n (%)
December–February 363 (21.9) 207 (17.7) 133 (31.7) 23 (32.9)
March–May 383 (23.1) 207 (17.7) 144 (34.4) 32 (45.7)
June–August 475 (28.7) 407 (34.8) 60 (14.3) 8 (11.4)
September–November 437 (26.4) 348 (29.8) 82 (19.6) 7 (10.0)
Education (n 5 1,655), n (%)
Did not finish high school 366 (22.1) 243 (20.8) 103 (24.7) 20 (28.6)
Finished high school/some college/vocational 910 (55.0) 644 (55.1) 226 (54.2) 40 (57.1)
College/professional 379 (22.9) 281 (24.1) 88 (21.1) 10 (14.3)
Female, n (%) 1,148 (69.2) 756 (64.7) 330 (78.8) 62 (88.6)
BMI, kg/m2, mean (SD) 26.5 (4.5) 26.1 (4.2) 27.7 (5.1) 27.4 (5.3)
Current smoker (n 5 1,615), n (%) 149 (9.2) 93 (8.2) 46 (11.2) 10 (14.7)
Alcohol use (n 5 1,656), n (%)a
Nondrinkers 898 (54.2) 613 (52.4) 245 (58.6) 40 (58.0)
Moderate drinkers 621 (37.5) 452 (38.7) 145 (34.7) 24 (34.8)
Heavy drinkers 137 (8.3) 104 (8.9) 28 (6.7) 5 (7.3)
Depressive symptoms (CES-D score ‡8), n (%) 359 (21.7) 221 (18.9) 117 (27.9) 21 (30.0)
Diabetes, n (%)b 175 (10.6) 95 (8.1) 64 (15.3) 16 (22.9)
Hypertension, n (%)
Normal 696 (42.0) 526 (45.0) 151 (36.0) 19 (27.1)
Treated 639 (38.5) 412 (35.2) 189 (45.1) 38 (54.3)
Untreated 323 (19.5) 231 (19.8) 79 (18.9) 13 (18.6)
Years of follow-up, mean (SD) 5.6 (1.6) 5.8 (1.5) 5.3 (1.8) 5.2 (1.6)
White, n (%) 1,452 (87.6) 1,088 (93.1) 322 (76.9) 42 (60.0)
Income, $, n (%)
<12,000 330 (19.9) 198 (16.9) 107 (25.5) 25 (35.7)
12,000–24,999 547 (33.0) 394 (33.7) 131 (31.3) 22 (31.4)
25,000–49,999 449 (27.1) 343 (29.3) 95 (22.7) 11 (15.7)
‡50,000 234 (14.1) 179 (15.3) 49 (11.7) 6 (8.6)
Missing 98 (5.9) 55 (4.7) 37 (8.8) 6 (8.6)
Occupation, n (%)
Professional/technical/managerial/administrative 611 (36.9) 452 (38.7) 135 (32.2) 24 (34.3)
Sales/clerical service 254 (15.3) 176 (15.1) 69 (16.5) 9 (12.9)
Craftsman/machine operator/laborer/farming/
forestry
219 (13.2) 159 (13.6) 47 (11.2) 13 (18.6)
Housewife 430 (25.9) 277 (23.7) 134 (32.0) 19 (27.1)
Other/missing 144 (8.7) 105 (9.0) 34 (8.1) 5 (7.1)
Abbreviations: 25(OH)D 5 25-hydroxyvitamin D; BMI 5 body mass index; CES-D 5 Center for Epidemiologic Studies
Depression Scale24 (revised 10-item scale); CHS 5 Cardiovascular Health Study.
aNational Institute on Alcohol Abuse and Alcoholism guidelines.
bAmerican Diabetes Association guidelines.
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technique.25 We analyzed serum 25(OH)D using clinically
relevant cutpoints: ,25 nmol/L (severely deficient), $25 nmol/L
to ,50 nmol/L (deficient), and $50 nmol/L (sufficient).26 Linear
trends across categories were tested by entering 25(OH)D
groups into models as a continuous rather than a categorical
variable. In basic adjusted models, we controlled for age and
season of blood collection. In fully adjusted models, we
controlled for education, sex, BMI, smoking, alcohol consumption,
and depressive symptoms. To investigate any threshold, we used
multivariate adjusted penalized smoothing spline plots. Eight
outlying participants with 25(OH)D concentrations between
170 and 283 nmol/L were excluded due to imprecision at the
extreme end of the distribution (none developed dementia
during follow-up).
In secondary analyses, serum 25(OH)D concentrations
were analyzed as a continuous rather than a categorical variable.
25(OH)D concentrations were standardized to have a mean of
0 and an SD of 1 to aid interpretation. Because 25(OH)D con-
centrations were positively skewed, they were normalized using
a log transformation. We repeated the main analyses to include
adjustments for health conditions that have been identi-
fied as potential mediators for the association between serum
25(OH)D concentrations and dementia risk12,13: diabetes
(American Diabetes Association guidelines: using oral hypogly-
cemic agents or insulin, or plasma fasting glucose$7.0 nmol/L)
and/or hypertension (3 categories; no hypertension: systolic
,140 mm Hg and diastolic ,90 mm Hg; treated hyperten-
sion: hypertensive medication; untreated hypertension:
systolic $140 mm Hg or diastolic $90 mm Hg with no hyper-
tensive medication). We also adjusted for ethnicity (white/black)
and examined potential interactions with ethnicity in separate mod-
els, although it is recognized that this may represent overadjust-
ment.27 In a further analysis, we adjusted for socioeconomic
status indicators: annual income (,$12,000, $12,000–24,999,
$25,000–49,999, $$50,000, missing) and usual lifetime occupa-
tion (professional/technical/managerial/administrative, sales/clerical
service, craftsman/machine operator/laborer/farming/forestry,
housewife, other/missing). Multivariate adjusted logistic regres-
sion models were used to investigate the cross-sectional associa-
tion between serum 25(OH)D and prevalent all-cause dementia
(n 5 69) and AD (n 5 34).
In sensitivity analyses, we excluded participants who devel-
oped all-cause dementia (n5 12) and AD (n5 6) within 1 year
of baseline to remove the possibility that any association
observed was determined by these “early converters.” p Values
were 2-sided throughout, and the type I error rate for statistical
significance was set at 0.05. Analyses were performed using
Stata SE version 12 (StataCorp, College Station, TX) with the
exception of the spline plots, which were fitted in R version
2.15.1 (www.r-project.org).
RESULTS Table 1 displays baseline characteristics
for the study population included in the main pro-
spective analyses. Participants were followed up for a
mean of 5.6 years (SD 1.6, median 6.1, range 0.1–
8.4). During 9,317.5 person-years of follow-up, 171
participants developed all-cause dementia and 102
developed AD. The risk of developing both all-cause
dementia and AD was significantly higher in
participants who were either 25(OH)D deficient
or severely deficient (table 2). In minimally
adjusted models, those who were deficient had
about a 51% increased risk of all-cause dementia,
whereas the increased risk for those who were
severely deficient was about 122%. The strength
of the association observed for incident AD was
similar to that observed for all-cause dementia.
Additional adjustment for potential confounders
did not alter the pattern of results, and there was a
linear trend across groups in all analyses, suggesting
a monotonic association. Kaplan-Meier plots for
unadjusted rates of incident all-cause dementia and
AD show clear differences in risk by 25(OH)D
concentrations after 2–3 years of follow-up (figure 1).
Multivariate adjusted smoothing spline plots suggest
that the risk of all-cause dementia and AD markedly
increases at 25(OH)D concentrations below 50 nmol/L
(figure 2).
Secondary analyses incorporating continuous
25(OH)D concentrations gave a similar pattern of
results. The multivariate adjusted risks for incident
all-cause dementia and incident AD reduced by 18%
(hazard ratio [HR] 5 0.82, 95% confidence interval
[CI]: 0.70–0.97, p 5 0.02) and 20% (HR 5 0.80,
95% CI: 0.65–0.99, p 5 0.04), respectively, for each
1 SD increase in log-transformed 25(OH)D.
Table 2 Cox proportional hazards regression models of incident all-cause dementia and Alzheimer disease by serum 25(OH)D concentration
Dementia status No. of participants No. of cases
Serum 25(OH)D, nmol/L
p Value for
linear trend‡50 ‡25 to <50, HR (95% CI) <25, HR (95% CI)
All-cause dementia
Model Aa 1,658 171 1 (reference) 1.51 (1.06–2.16) 2.22 (1.23–4.02) 0.002
Model Bb 1,615 168 1 (reference) 1.53 (1.06–2.21) 2.25 (1.23–4.13) 0.002
Alzheimer disease
Model Aa 1,589 102 1 (reference) 1.67 (1.06–2.62) 2.27 (1.06–4.84) 0.006
Model Bb 1,547 100 1 (reference) 1.69 (1.06–2.69) 2.22 (1.02–4.83) 0.008
Abbreviations: 25(OH)D 5 25-hydroxyvitamin D; CI 5 confidence interval; HR 5 hazard ratio.
a Adjusted for age and season of vitamin D collection.
bAdjusted for model A and education, sex, BMI, smoking, alcohol consumption, and depressive symptoms.
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Additional adjustment for diabetes or hypertension
did not change the pattern of results for either inci-
dent all-cause dementia or AD, suggesting that these
conditions are unlikely to mediate the observed asso-
ciations (table 3). Adjustment for ethnicity attenu-
ated the main results slightly but did not change the
overall pattern of results, and there were no signifi-
cant interactions (table e-1 on the Neurology® Web
site at Neurology.org). Additional adjustment for
income and occupation did not change the associa-
tions either (table e-2). The odds of prevalent all-
cause dementia and AD at baseline in participants
who were severely 25(OH)D deficient were 3–6
times higher than those with sufficient 25(OH)D,
with a linear trend across groups (table e-3). After
excluding participants who developed all-cause
dementia and AD within 1 year of baseline, the mul-
tivariate adjusted HRs in participants who were
severely 25(OH)D deficient and deficient compared
to participants with sufficient 25(OH)D concentra-
tions were 2.42 (95% CI: 1.33–4.39) and 1.54 (95%
CI: 1.06–2.28) for incident all-cause dementia (p for
linear trend5 0.001) and 2.36 (95% CI: 1.08–5.16)
and 1.69 (95% CI: 1.04–2.73) for AD (p for linear
trend 5 0.007). This suggests that the association is
not driven by “early converters.”
Figure 1 Kaplan-Meier curves for unadjusted rates of all-cause dementia and Alzheimer disease by serum 25-hydroxyvitamin D (25(OH)D)
concentrations.
Figure 2 Multivariate adjusted smoothing spline plots showing the hazard ratios for dementia and Alzheimer disease by serum 25(OH)D
concentrations
Models adjusted for age, season of vitamin D collection, education, sex, body mass index, smoking, alcohol consumption, and depressive symptoms. Hazard
ratios centered on median serum 25-hydroxyvitamin D (25(OH)D) concentrations.
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DISCUSSION We have conducted what is to our
knowledge the first large, prospective, population-
based study to examine vitamin D concentrations in
relation to a comprehensive adjudicated assessment of
dementia and AD. We observed a strong monotonic
association between 25(OH)D concentrations and
the risk of both incident all-cause dementia and AD.
This association was robust to adjustment for a range
of potential confounders and the exclusion of
dementia cases that occurred within a year of baseline.
The 2 previous studies that have investigated vita-
min D and incident dementia have produced con-
flicting results. The first found that severe vitamin
D deficiency was associated with non-AD dementia
but not AD risk.16 The second found that severe vita-
min D deficiency was associated with AD but not
vascular dementia risk.17 However, the first study
incorporated a small sample of high-functioning
women (n 5 40), and the lack of association with
AD may reflect limited statistical power. The second
study relied on registry data for dementia diagnoses,
which may have resulted in considerable misclassifi-
cation. Our results establish that low 25(OH)D con-
centrations are linked to an increased risk of incident
all-cause dementia and AD, and they are consistent
with studies suggesting a link with cognitive impair-
ment1,3,12,26,28 and cognitive decline.13–15 Few studies
have examined potential mediators of this association,
although there was no evidence in the present study
or the InCHIANTI13 study for mediation by diabetes
or hypertension.
A threshold below which the risk of dementia in-
creases markedly has previously been hypothesized to
lie in the 25–50 nmol/L range.12 The optimal level of
vitamin D for general health remains controversial,
with the Institute of Medicine recommending
50 nmol/L and the Endocrine Society recommending
75 nmol/L.29,30 A post hoc analysis of the Women’s
Health Initiative randomized controlled trial discov-
ered that a relatively low dose of vitamin D (400 IU)
in combination with calcium (1,000 mg) did not pro-
tect against dementia over a mean follow-up period of
7.8 years in women who had relatively high serum
vitamin D levels at baseline (mean of 49 nmol/L
in a small subsample).31 Our results clarify that the
threshold above which older adults are unlikely to
benefit from supplementation with regard to demen-
tia risk is likely to lie in the region of 50 nmol/L
when 25(OH)D concentrations are measured using
LC-MS. This therefore adds to the ongoing debate
regarding optimal vitamin D levels for different
health outcomes.
A number of potential mechanisms linking low
vitamin D levels with the risk of dementia have been
identified.32 Vitamin D receptors are expressed
throughout the brain, including areas involved in
memory such as the hippocampus and dentate gyrus.6
Similarly, the enzyme that synthesizes the active form
of vitamin D, 1a-hydroxylase, is produced in several
cerebral regions. The active form of vitamin D,
1,25dihydroxy-vitamin D3 (1,25-D3), regulates neu-
rotrophin expression, such as nerve growth factor,
neurotrophin 3, and glial-derived neurotrophic fac-
tor,11 and the survival, development, and function of
neural cells.33 In vitro, vitamin D stimulates macro-
phages, which increases the clearance of amyloid pla-
ques, a hallmark of AD.7,8 Vitamin D also reduces
amyloid-induced cytotoxicity and apoptosis in pri-
mary cortical neurons.9 A recent study found that amy-
loid-b induction of induced nitric oxide synthase, part
of the inflammatory process of AD, is dependent on the
disruption of the vitamin D-vitamin D receptor path-
way.34 Vitamin D supplementation ameliorates age-
related decline in learning and memory in aged rats.35
Table 3 Cox proportional hazards regression models of incident all-cause dementia and Alzheimer disease by serum 25(OH)D concentration
with additional adjustment for potential mediators
Dementia statusa
No. of
Participants No. of cases
Serum 25(OH)D, nmol/L
‡50
‡25 to <50,
HR (95% CI) <25, HR (95% CI)
p Value for
linear trend
All-cause dementia
Diabetes 1,615 168 1 (reference) 1.50 (1.04–2.17) 2.18 (1.18–4.01) 0.003
Hypertension 1,615 168 1 (reference) 1.52 (1.05–2.20) 2.24 (1.22–4.12) 0.002
Diabetes and hypertension 1,615 168 1 (reference) 1.50 (1.04–2.17) 2.18 (1.18–4.02) 0.003
Alzheimer disease
Diabetes 1,547 100 1 (reference) 1.65 (1.03–2.63) 2.14 (0.98–4.68) 0.01
Hypertension 1,547 100 1 (reference) 1.69 (1.05–2.69) 2.26 (1.04–4.90) 0.008
Diabetes and hypertension 1,547 100 1 (reference) 1.65 (1.03–2.65) 2.20 (1.01–4.80) 0.01
Abbreviations: 25(OH)D 5 25-hydroxyvitamin D; BMI 5 body mass index; CI 5 confidence interval; HR 5 hazard ratio.
aModels also adjusted for age, season of vitamin D collection, education, sex, BMI, smoking, alcohol consumption, and depressive symptoms.
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In addition, vitamin D deficiency has been linked to
cerebrovascular pathology. Meta-analyses establish that
25(OH)D deficiency is associated with an increased risk
of incident stroke,36 particularly ischemic stroke.10 A
cross-sectional study of 318 elderly adults found that
25(OH)D deficiency was associated with increased
white matter hyperintensity volume and a greater num-
ber of large vessel infarcts.37 In summary, low vitamin D
concentrations may increase the risk of dementia and
AD through both neurodegenerative and vascular
mechanisms.
Our study has a number of strengths. The study
sample was relatively diverse as it was population-
based and included white and African-American
men and women. A recent systematic review raised
the possibility that the consistent observational associ-
ations between vitamin D levels and a wide range of
health conditions may simply reflect reverse causa-
tion.38 However, in this study reverse causation is
made less likely by the fact that participants were
ambulatory and relatively healthy at baseline (their
outdoor activity was not likely to be limited by
impaired function linked to the onset of dementia).
The long follow-up and exclusion of prevalent
dementia and incident dementia occurring within a
year of baseline also make reverse causation less likely.
All-cause dementia and AD in the CHS were diag-
nosed by a committee of neurologists and psychia-
trists using a comprehensive range of data, including
neuroimaging, according to international criteria
(NINCDS-ADRDA).23 Our study also has several
limitations. While the CHS is multiethnic, it did
not incorporate people of Hispanic or other ethnic-
ities. Due to the exclusion of participants with cardi-
ovascular disease and stroke at baseline, there were
few cases of incident vascular dementia (n 5 15). It
was therefore not possible to investigate the relation-
ship between vitamin D concentrations and incident
vascular dementia due to a lack of statistical power,
and further research is necessary to investigate gener-
alizability to older adults with vascular dysfunction.
In a cohort with a greater burden of vascular and
metabolic dysfunction it would also be interesting
to investigate these factors as time-varying covariates.
The representativeness of our final sample may have
been reduced due to the inability to include partic-
ipants with insufficient serum volume for 25(OH)D
measurement (n 5 945) as well as those lost to
follow-up (n 5 596). It is possible that the delay
between obtaining the blood samples in 1992–1993
and measuring 25(OH)D concentrations in 2008
could have introduced measurement error; however,
this is unlikely to have introduced systematic bias.
Despite the wide range of information (including
repeat neuroimaging) available to the committee
diagnosing all-cause dementia and AD, a degree of
misclassification is still likely. In particular, many
cases of AD may actually reflect a mixture of pathol-
ogies, so caution should be exercised when consider-
ing potential mechanisms. As with all observational
studies, unmeasured confounding is possible, and our
findings do not in themselves demonstrate a causal
relationship.
We found a strong association between baseline
vitamin D concentrations and the risk of incident
all-cause dementia and AD over a mean of 5.6 years
of follow-up in ambulatory older adults free from vas-
cular conditions at baseline. Further studies are neces-
sary to replicate our findings and extend them to
more diverse populations. It would be useful to con-
duct prospective studies to investigate the association
between vitamin D concentrations and incident vas-
cular dementia and neuroimaging abnormalities.
Our findings support the hypothesis that vitamin D
may be neuroprotective and that “sufficiency” in
the context of dementia risk may be in the region
of 50 nmol/L. This information is likely to prove
useful in improving the design and reducing the cost
of randomized controlled trials investigating whether
vitamin D supplements can be used to delay or pre-
vent the onset of dementia and AD in older adults.
AUTHOR CONTRIBUTIONS
Mr. Littlejohns: drafting and revising the manuscript for content, study
concept and design, analysis and interpretation of data, and statistical
analysis. Dr. Henley: revising the manuscript for content, study concept
and design, analysis and interpretation of data, and statistical analysis.
Dr. Lang: revising the manuscript for content, interpretation of data.
Dr. Annweiler: revising the manuscript for content, interpretation of
data. Dr. Beauchet: revising the manuscript for content, interpretation
of data. Dr. Chaves: revising the manuscript for content, interpretation
of data, obtaining funding. Dr. Fried: revising the manuscript for con-
tent, interpretation of data, acquisition of data. Dr. Kestenbaum: revising
the manuscript for content, interpretation of data, acquisition of data, ob-
taining funding. Dr. Kuller: revising the manuscript for content, interpre-
tation of data, acquisition of data. Dr. Langa: revising the manuscript for
content, interpretation of data, acquisition of data, obtaining funding.
Dr. Lopez: revising the manuscript for content, interpretation of data,
acquisition of data. Dr. Kos: revising the manuscript for content, study
concept and design, analysis and interpretation of data. Dr. Soni: revising
the manuscript for content, study concept and design, analysis and inter-
pretation of data, statistical analysis. Dr. Llewellyn: drafting and revising
the manuscript for content, study concept and design, analysis and inter-
pretation of data, acquisition of data, statistical analysis, study supervision
and coordination, obtaining funding.
STUDY FUNDING
The CHS was supported by contracts HHSN268201200036C,
HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080,
N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grant
HL080295 from the National Heart, Lung, and Blood Institute, with addi-
tional contribution from the National Institute of Neurological Disorders
and Stroke. Additional support was provided by AG023629, AG20098,
AG15928, and HL084443 from the National Institute on Aging. A full list
of principal CHS investigators and institutions can be found at www.chs-
nhlbi.org. Additional support was also provided by NIRG-11-200737 from
the Alzheimer’s Association, the Mary Kinross Charitable Trust, the James
Tudor Foundation, the Halpin Trust, the Age Related Diseases and Health
Trust, and the Norman Family Charitable Trust (to D.J.L.). This report
926 Neurology 83 September 2, 2014
presents independent research supported by the UK National Institute for
Health Research (NIHR) Collaboration for Leadership in Applied Health
Research and Care (CLAHRC) for the South West Peninsula. None of the
funding sources had any role in the design of the study; in the analysis and
interpretation of the data; or in the preparation of the manuscript. The views
expressed in this publication are those of the authors and not necessarily
those of the NHS, the NIHR, or the Department of Health in England. The
NIH was involved in the original design and conduct of the CHS and in the
data collection methods.
DISCLOSURE
The authors report no disclosures relevant to the manuscript. Go to
Neurology.org for full disclosures.
Received February 3, 2014. Accepted in final form May 28, 2014.
REFERENCES
1. Balion C, Griffith LE, Strifler L, et al. Vitamin D, cogni-
tion, and dementia: a systematic review and meta-analysis.
Neurology 2012;79:1397–1405.
2. Annweiler C, Llewellyn DJ, Beauchet O. Low serum vita-
min D concentrations in Alzheimer’s disease: a systematic
review and meta-analysis. J Alzheimers Dis 2013;33:659–
674.
3. Annweiler C, Montero-Odasso M, Llewellyn DJ, Richard-
Devantoy S, Duque G, Beauchet O. Meta-analysis of
memory and executive dysfunctions in relation to vitamin
D. J Alzheimers Dis 2013;37:147–171.
4. Holick MF. Vitamin D deficiency. N Engl J Med 2007;
357:266–281.
5. Thies W, Bleiler L. 2013 Alzheimer’s disease facts and
figures. Alzheimers Dement 2013;9:208–245.
6. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ.
Distribution of the vitamin D receptor and 1 alpha-
hydroxylase in human brain. J Chem Neuroanat 2005;
29:21–30.
7. Masoumi A, Goldenson B, Ghirmai S, et al. 1alpha,25-
dihydroxyvitamin D3 interacts with curcuminoids to
stimulate amyloid-beta clearance by macrophages of Alz-
heimer’s disease patients. J Alzheimers Dis 2009;17:703–
717.
8. Mizwicki MT, Menegaz D, Zhang J, et al. Genomic and
nongenomic signaling induced by 1a,25(OH)2-vitamin
D3 promotes the recovery of amyloid-b phagocytosis by
Alzheimer’s disease macrophages. J Alzheimers Dis 2012;
29:51–62.
9. Dursun E, Gezen-Ak D, Yilmazer S. A novel perspective
for Alzheimer’s disease: vitamin D receptor suppression by
amyloid-b and preventing the amyloid-b induced altera-
tions by vitamin D in cortical neurons. J Alzheimers Dis
2011;23:207–219.
10. Brøndum-Jacobsen P, Nordestgaard BG, Schnohr P,
Benn M. 25-hydroxyvitamin D and symptomatic ischemic
stroke: an original study and meta-analysis. Ann Neurol
2013;73:38–47.
11. Annweiler C, Montero-Odasso M, Hachinski V,
Seshadri S, Bartha R, Beauchet O. Vitamin D concentra-
tion and lateral cerebral ventricle volume in older adults.
Mol Nutr Food Res 2013;57:267–276.
12. Dickens AP, Lang IA, Langa KM, Kos K, Llewellyn DJ.
Vitamin D, cognitive dysfunction and dementia in older
adults. CNS Drugs 2011;25:629–639.
13. Llewellyn DJ, Lang IA, Langa KM, et al. Vitamin D and
risk of cognitive decline in elderly persons. Arch Intern
Med 2010;170:1135–1141.
14. Slinin Y, Paudel ML, Taylor BC, et al. 25-
Hydroxyvitamin D levels and cognitive performance and
decline in elderly men. Neurology 2010;74:33–41.
15. Slinin Y, Paudel M, Taylor BC, et al. Association between
serum 25(OH) vitamin D and the risk of cognitive decline
in older women. J Gerontol A Biol Sci Med Sci 2012;67:
1092–1098.
16. Annweiler C, Rolland Y, Schott AM, Blain H, Vellas B,
Beauchet O. Serum vitamin D deficiency as a predictor of
incident non-Alzheimer dementias: a 7-year longitudinal
study. Dement Geriatr Cogn Disord 2011;32:273–278.
17. Afzal S, Bojesen SE, Nordestgaard BG. Reduced 25-
hydroxyvitamin D and risk of Alzheimer’s disease and vas-
cular dementia. Alzheimers Dement 2014;10:296–302.
18. Fried LP, Borhani NO, Enright P, et al. The Cardiovas-
cular Health Study: design and rationale. Ann Epidemiol
1991;1:263–276.
19. Kestenbaum B, Katz R, de Boer I, et al. Vitamin D, par-
athyroid hormone, and cardiovascular events among older
adults. J Am Coll Cardiol 2011;58:1433–1441.
20. Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and
prevalence of dementia in the Cardiovascular Health
Study. J Am Geriatr Soc 2004;52:195–204.
21. De Boer IH, Levin G, Robinson-Cohen C, et al. Serum
25-hydroxyvitamin D concentration and risk for major
clinical disease events in a community-based population
of older adults: a cohort study. Ann Intern Med 2012;156:
627–634.
22. Phinney KW. Development of a standard reference mate-
rial for vitamin D in serum. Am J Clin Nutr 2008;88:
511S–512S.
23. Lopez OL, Kuller LH, Fitzpatrick A, Ives D, Becker JT,
Beauchamp N. Evaluation of dementia in the cardiovas-
cular health cognition study. Neuroepidemiology 2003;
22:1–12.
24. Radloff L. The CES-D scale: a self-report depression scale
for research in the general population. Appl Psychol Meas
1977;1:385–401.
25. Schoenfeld D. Partial residuals for the proportional haz-
ards regression model. Biometrika 1982;69:239–241.
26. Llewellyn DJ, Lang IA, Langa KM, Melzer D. Vitamin D
and cognitive impairment in the elderly U.S. population.
J Gerontol A Biol Sci Med Sci 2011;66:59–65.
27. Brehm JM, Schuemann B, Fuhlbrigge AL, et al. Serum
vitamin D levels and severe asthma exacerbations in the
Childhood Asthma Management Program study. J Allergy
Clin Immunol 2010;126:52–58.e5.
28. Llewellyn D, Langa K. Serum 25-hydroxyvitamin D con-
centration and cognitive impairment. J Geriatr Psychiatry
2009;22:188–195.
29. Institute of Medicine. Dietary Reference Intakes for Cal-
cium and Vitamin D. Washington, DC: National Acade-
mies Press; 2011.
30. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Eval-
uation, treatment, and prevention of vitamin D deficiency:
an Endocrine Society clinical practice guideline. J Clin
Endocrinol Metab 2011;96:1911–1930.
31. Rossom RC, Espeland MA, Manson JE, et al. Calcium
and vitamin D supplementation and cognitive impairment
in the women’s health initiative. J Am Geriatr Soc 2012;
60:2197–2205.
32. Gezen-Ak D, Yilmazer S, Dursun E. Why vitamin D in
Alzheimer’s disease? the hypothesis. J Alzheimers Dis
2014;40:257–269.
Neurology 83 September 2, 2014 927
33. Fernandes de Abreu DA, Eyles D, Féron F. Vitamin D, a
neuro-immunomodulator: implications for neurodegener-
ative and autoimmune diseases. Psychoneuroendocrinol-
ogy 2009;34(suppl 1):S265–S277.
34. Dursun E, Gezen-Ak D, Yilmazer S. A new mechanism for
amyloid-b induction of iNOS: vitamin D-VDR pathway
disruption. J Alzheimers Dis 2013;36:459–474.
35. Briones TL, Darwish H. Vitamin D mitigates age-related cog-
nitive decline through the modulation of pro-inflammatory
state and decrease in amyloid burden. J Neuroinflammation
2012;9:244.
36. Wang L, Song Y, Manson JE, et al. Circulating 25-
hydroxy-vitamin D and risk of cardiovascular disease: a
meta-analysis of prospective studies. Circ Cardiovasc Qual
Outcomes 2012;5:819–829.
37. Buell JS, Weiner DE, Tucker L, Usda JM. 25-Hydrox-
yvitamin D, dementia, and cerebrovascular pathology in
elders receiving home services. Neurology 2010;74:18–
26.
38. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status
and ill health: a systematic review. Lancet Diabetes Endo-
crinol 2014;2:76–89.
You’re Committed to Continually Expanding Your
Knowledge
NeuroSAE™ is committed to helping you. The Sixth Edition of the AAN’s convenient online self-
assessment examination is now available, featuring 150 questions and 8 self-assessment CME
credits upon successful completion to help meet ABPN MOC requirements.
See all the available NeuroSAE versions and purchase the exam today at AAN.com/view/neuroSAE.
2014 AAN Annual Meeting On Demand
Take the meeting with you. AAN Annual Meeting On Demand is the comprehensive digital
library of presentations from the 2014 Annual Meeting providing more than 500 hours* of
educational content.
Order now at AANonDemand.com
*Total hours of presentations available subject to speaker permissions.
Share Your Artistic Expressions in Neurology ‘Visions’
AAN members are urged to submit medically or scientifically related artistic images, such as photo-
graphs, photomicrographs, and paintings, to the “Visions” section of Neurology®. These images are
creative in nature, rather than the medically instructive images published in the NeuroImages sec-
tion. The image or series of up to six images may be black and white or color and must fit into one
published journal page. Accompanying description should be 100 words or less; the title should be a
maximum of 96 characters including spaces and punctuation.
Learn more at www.aan.com/view/Visions, or upload a Visions submission at submit.neurology.org.
928 Neurology 83 September 2, 2014
